KalVista Pharmaceuticals is developing novel plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, the leading cause of adult visual loss in developed countries.
Latest News
KalVista Pharmaceuticals and JDRF form research partnership focused on novel approach for treating diabetic eye disease
KalVista Pharmaceuticals Launched with £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
|
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema